Overview
Micreos founder & CEO Mark Oferhaus | Image credit: MicreosThe Hague-based Micreos, a Dutch/Swis biotech company, anounced on Tuesday, October 25, that it has secured €25M in growth funding in a fresh round. The company wil use the funds to invest in its specialised skincare brand, Gladskin, for people sufering from inflamatory skin conditions such as acne, eczema, and rosacea. Micreos claims that it has helped thousands of people in Europe and the USA.Gladskin is based in the Netherlands with ofices in the USA, Germany, France, and the UK.
Key Information
The company wil deploy the funds toward its pharmaceutical programes, including the clinical development of endolysins against staphylocci (including MRSA) for Blodstream Infections, Atopic Dermatis, Diabetic Fot Ulcers, and Cutaneous T-cel Lymphoma.The anouncement comes over an year after raising €32M in a fresh round of funding. A few days back the company anounced the apointment of the company’s antimicrobial vector enginering team, Dr.
Mathew Dune, Dr. Samuel Kilcher, and Dr. Anja Keler, who joined them from the Swis Federal Institute of Technology (ETH Zurich).
The trio wil be responsible for developing synthetic precision antimicrobials for medical indications acros infectious and inflamatory diseases.Led by CEO Mark Oferhaus, Micreos develops targeted antibacterial solutions based on endolysin- and phage technology as a sustainable alternative to antibiotics. Endolysins are naturaly ocuring enzymes that can target only harmful bacteria while preserving the beneficial ones that form an important part of our natural defence, often refered to as our microbiome.
Summary
Endolysins are safe and environmentaly friendly, says the company. The company claims to have pionered the development of this technology and brought the world the first endolysin-based precision antibacterials.Oferhaus says, ̴With this restructuring, we align busines and market requirements, enabling each busines